| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ETNK1 |
| Uniprot No | Q9HBU6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-169aa |
| 氨基酸序列 | MANYIHVPPGSPEVPKLNVTVQDQEEHRCREGALSLLQHLRPHWDPQEVTLQLFTDGITNKLIGCYVGNTMEDVVLVRIYGNKTELLVDRDEEVKSFRVLQAHGCAPQLYCTFNNGLCYEFIQGEALDPKHVCNPAIFSLSSLTLCKGKTTRCFGLTGCRGSRLLLSFF |
| 分子量 | 44.22 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于重组人ETNK1蛋白的文献示例(注：以下内容基于模拟文献，实际文献可能需要通过学术数据库检索确认)：
---
1. **文献名称**: "Structural and Functional Characterization of Human Ethanolamine Kinase 1 (ETNK1)"
**作者**: Smith, J., et al.
**摘要**: 该研究解析了重组人ETNK1蛋白的晶体结构，揭示了其催化乙醇胺磷酸化的关键活性位点，并证明其突变体(R233G)与先天性代谢紊乱相关，导致磷脂合成异常。
2. **文献名称**: "ETNK1 Promotes Mitochondrial Metabolism and Tumor Progression in Colorectal Cancer"
**作者**: Li, Y., et al.
**摘要**: 通过体外表达重组ETNK1蛋白，研究发现其通过调控磷脂酰乙醇胺合成影响线粒体膜稳定性，进而促进结直肠癌细胞增殖和代谢重编程。
3. **文献名称**: "Development of a High-Throughput Assay for Ethanolamine Kinase Activity Using Recombinant ETNK1"
**作者**: Gonzalez, R., et al.
**摘要**: 该文献报道了一种基于重组ETNK1蛋白的高通量酶活检测方法，用于筛选小分子抑制剂，为ETNK1相关疾病的药物开发提供技术支持。
4. **文献名称**: "Role of ETNK1 in Hepatic Phospholipid Biosynthesis and Its Regulation by Insulin"
**作者**: Tanaka, K., et al.
**摘要**: 研究发现重组ETNK1蛋白在肝细胞中受胰岛素信号通路调控，其表达水平变化直接影响磷脂酰乙醇胺合成，并与非酒精性脂肪肝疾病(NAFLD)的进展相关。
---
**提示**：若需具体文献，建议通过PubMed、Web of Science等平台检索关键词“ETNK1 recombinant protein”或“ETNK1 function”获取最新研究。
Recombinant human ETNK1 (ethanolamine kinase 1) protein is a key enzyme produced through genetic engineering to study cellular phospholipid metabolism. ETNK1 catalyzes the ATP-dependent phosphorylation of ethanolamine to form phosphoethanolamine, a critical step in the Kennedy pathway for synthesizing phosphatidylethanolamine (PE)—an essential phospholipid in cell membranes. Dysregulation of PE biosynthesis is linked to metabolic disorders, neurological conditions, and cancer progression.
Researchers utilize recombinant ETNK1 to investigate its enzymatic activity, structural properties, and interactions with substrates or inhibitors. This protein is typically expressed in prokaryotic (e.g., E. coli) or eukaryotic systems to ensure proper folding and post-translational modifications. Its applications span drug discovery for metabolic diseases, studies of membrane dynamics in neurodegeneration (e.g., Alzheimer’s), and cancer biology, where altered lipid metabolism supports tumor growth.
Current challenges include elucidating ETNK1’s regulatory mechanisms in different tissues and its crosstalk with other lipid biosynthesis pathways. Structural studies using recombinant ETNK1 aim to reveal substrate-binding domains and potential therapeutic targets. Despite progress, its role in disease-specific lipid reprogramming remains underexplored, necessitating further functional assays and in vivo models. Commercial availability of recombinant ETNK1 accelerates mechanistic studies while ensuring batch-to-batch consistency.
×
